A simple in vitro method for evaluating dendritic cell-based vaccinations

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1455-1464

  Van Pham, Phuc ^a   Nguyen, Nhung Thi ^a   Nguyen, Hoang Minh ^a   Khuat, Lam Tan ^a   Le, Phong Minh ^a   Pham, Viet Quoc ^a   Nguyen, Sinh Truong ^a   Phan, Ngoc Kim ^a  

^a UNIVERSITY OF NATURAL SCIENCES   (Viet Nam)

Author keywords

CTLs; Cytotoxicity assay; Dendritic cells; Immunotherapy; Targeting therapy

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL PHAGOCYTOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN;

EID: 84907331822     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S67057     Document Type: Article

References (34)

1. Lasky JL3rd, Panosyan EH, Plant A, et al. Autologous tumor lysatepulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 2013;33(5):2047-2056.
2. Bauer C, Dauer M, Saraj S, et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother.2011;60(8):1097-1107.
3. Burgdorf SK. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull.2010;57(9):B4171.
4. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in15 individual patients. J Cancer Res Clin Oncol.2003;129(9):521-530.
5. Baek S, Kim CS, Kim SB, et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med.2011;9:178.
6. Gao D, Li C, Xie X, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PloS One.2014;9(4):e93886.
7. Zhan HL, Gao X, Pu XY, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl).2012;125(21):3771-3777.
8. Fu X, Tao L, Rivera A, et al. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PloS One.2010;5(7): e11867.
9. Lemonnier FA. Evaluating CD8 + T cell responses in vitro. Methods Mol Biol.2013;960:261-277.
10. Höppner M, Luhm J, Schlenke P, Koritke P, Frohn C. A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells. J Immunol Methods.2002;267(2):157-163.
11. van Baalen CA, Gruters RA, Berkhoff EG, Osterhaus AD, Rimmelzwaan GF. FATT-CTL assay for detection of antigen-specific cell-mediated cytotoxicity. Cytometry A.2008;73(11):1058-1065.
12. Chen K, Chen L, Zhao P, et al. FL-CTL assay: fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells. J Immunol Methods. 2005;300(1-2):100-114.
13. Jerome KR, Sloan DD, Aubert M. Measurement of CTL-induced cytotoxicity: the caspase3assay. Apoptosis.2003;8(6):563-571.
14. He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase3 in target cells. J Immunol Methods. 2005;304(1-2):43-59.
15. Nakagawa Y, Watari E, Shimizu M, Takahashi H. One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry. Biomed Res.2011;32(2):159-166.
16. Kim RJ, Park JR, Roh KJ, et al. High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2α. Cancer Lett.2013;333(1):18-31.
17. Guan N, Deng J, Li T, Xu X, Irelan JT, Wang MW. Label-free monitoring of T cell activation by the impedance-based xCELLigence system. Mol Biosyst.2013;9(5):1035-1043.
18. Zhuang X, Zhang W, Chen Y, et al. Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatableto oncolytic herpes simplex virus type1. BMC Cancer.2012;12:549.
19. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell.2007;1(5):555-567.
20. Schreurs MW, Eggert AA, de Boer AJ, Figdor CG, Adema GJ. Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur J Immunol.1999;29(9):2835-2841.
21. Phuc PV, Lam DH, Ngoc VB, Thu DT, Nguyet NT, Ngoc PK. Production of functional dendritic cells from menstrual blood-a new dendritic cell source for immune therapy. In Vitro Cell Dev Biol Anim. 2011;47(5-6):368-375.
22. van Rijt LS, Vos N, Willart M, et al. Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not reactivation, of TH2 effector responses in a mouse model of asthma. J Allergy Clin Immunol.2004;114(1):166-173.
23. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev.1996;153:47-83.
24. Lanier LL, O'Fallon S, Somoza C, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995;154(1):97-105.
25. Henry CJ, Ornelles DA, Mitchell LM, Brzoza-Lewis KL, Hiltbold EM. IL-12 produced by dendritic cells augments CD8+T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol.2008;181(12):8576-8584.
26. Nizzoli G, Krietsch J, Weick A, et al. Human CD1c+dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood.2013;122(6):932-942.
27. Yu N, Atienza JM, Bernard J, et al. Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal Chem.2006; 78(1):35-43.
28. Alborzinia H, Can S, Holenya P, et al. Real-time monitoring of cisplatininduced cell death. PloS One.2011;6(5):e19714.
29. Kramer AH, Joos-Vandewalle J, Edkins AL, Frost CL, Prinsloo E. Real-time monitoring of3T3-L1 preadipocyte differentiation using a commercially available electric cell-substrate impedance sensor system. Biochem Biophys Res Commun.2014;443(4):1245-1250.
30. Hasan M, Belhaj N, Benachour H, et al. Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation. Int J Pharm.2014;461(1-2):519-528.
31. Charwat V, Rothbauer M, Tedde SF, et al. Monitoring dynamic interactions of tumor cells with tissue and immune cells in a lab-on-achip. Anal Chem.2013;85(23):11471-11478.
32. Jun HS, Dao LT, Pyun JC, Cho S. Effect of cell senescence on the impedance measurement of adipose tissue-derived stem cells. Enzyme Microb Technol.2013;53(5):302-306.
33. Moe B, Gabos S, Li XF. Real-time cell-microelectronic sensing of nanoparticle-induced cytotoxic effects. Anal Chim Acta. 2013;789:83-90.
34. Moodley K, Angel CE, Glass M, Graham ES. Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. J Neurosci Methods.2011;200(2):173-180.